Cargando…

Cystitis and Utipro(®) Plus: Real-World Evidence

Background: The emergence of drug resistance in the etiological agents of uncomplicated urinary tract infections (UTIs) emphasizes the need to shift the paradigm towards alternative therapeutic strategies. The objective of the present study was to evaluate the use of a medical device containing xylo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostev, Karel, Cai, Tommaso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531070/
https://www.ncbi.nlm.nih.gov/pubmed/37761761
http://dx.doi.org/10.3390/healthcare11182564
_version_ 1785111634569592832
author Kostev, Karel
Cai, Tommaso
author_facet Kostev, Karel
Cai, Tommaso
author_sort Kostev, Karel
collection PubMed
description Background: The emergence of drug resistance in the etiological agents of uncomplicated urinary tract infections (UTIs) emphasizes the need to shift the paradigm towards alternative therapeutic strategies. The objective of the present study was to evaluate the use of a medical device containing xyloglucan, hibiscus, and propolis for reducing UTI symptomatic episodes, antibiotic prescription, and days of sick leave. Materials and Methods: It used retrospective, cross-sectional study data provided by office-based physicians from Germany (Disease Analyzer, IQVIA database), including those on 3586 patients with a diagnosis of UTI treated with Utipro(®) Plus (Noventure, Barcelona, Spain) from January 2015 to December 2020. Results: The majority of patients were women (94.2%) and had a mean age (standard deviation, SD) of 57.7 years (19.0). Within 12 months after the prescription and compared to the 12 months before, it was observed that there was a reduction in the proportion of patients with at least one UTI diagnosis (from 79.4% to 36.4%, p < 0.001), in antibiotic prescriptions (from 33.5% to 22.1%, p < 0.001), and in the proportion of patients with at least one day of sick leave (from 4.1% to 2.7%). Conclusions: The use of Utipro(®) Plus is able to decrease UTI recurrence and can lead to the reduction of antibiotic prescriptions and disease burden in individuals affected by uncomplicated cystitis.
format Online
Article
Text
id pubmed-10531070
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105310702023-09-28 Cystitis and Utipro(®) Plus: Real-World Evidence Kostev, Karel Cai, Tommaso Healthcare (Basel) Article Background: The emergence of drug resistance in the etiological agents of uncomplicated urinary tract infections (UTIs) emphasizes the need to shift the paradigm towards alternative therapeutic strategies. The objective of the present study was to evaluate the use of a medical device containing xyloglucan, hibiscus, and propolis for reducing UTI symptomatic episodes, antibiotic prescription, and days of sick leave. Materials and Methods: It used retrospective, cross-sectional study data provided by office-based physicians from Germany (Disease Analyzer, IQVIA database), including those on 3586 patients with a diagnosis of UTI treated with Utipro(®) Plus (Noventure, Barcelona, Spain) from January 2015 to December 2020. Results: The majority of patients were women (94.2%) and had a mean age (standard deviation, SD) of 57.7 years (19.0). Within 12 months after the prescription and compared to the 12 months before, it was observed that there was a reduction in the proportion of patients with at least one UTI diagnosis (from 79.4% to 36.4%, p < 0.001), in antibiotic prescriptions (from 33.5% to 22.1%, p < 0.001), and in the proportion of patients with at least one day of sick leave (from 4.1% to 2.7%). Conclusions: The use of Utipro(®) Plus is able to decrease UTI recurrence and can lead to the reduction of antibiotic prescriptions and disease burden in individuals affected by uncomplicated cystitis. MDPI 2023-09-16 /pmc/articles/PMC10531070/ /pubmed/37761761 http://dx.doi.org/10.3390/healthcare11182564 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kostev, Karel
Cai, Tommaso
Cystitis and Utipro(®) Plus: Real-World Evidence
title Cystitis and Utipro(®) Plus: Real-World Evidence
title_full Cystitis and Utipro(®) Plus: Real-World Evidence
title_fullStr Cystitis and Utipro(®) Plus: Real-World Evidence
title_full_unstemmed Cystitis and Utipro(®) Plus: Real-World Evidence
title_short Cystitis and Utipro(®) Plus: Real-World Evidence
title_sort cystitis and utipro(®) plus: real-world evidence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531070/
https://www.ncbi.nlm.nih.gov/pubmed/37761761
http://dx.doi.org/10.3390/healthcare11182564
work_keys_str_mv AT kostevkarel cystitisandutiproplusrealworldevidence
AT caitommaso cystitisandutiproplusrealworldevidence